MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote
- GLAND PHARMA
GLAND PHARMA Share Price (GLAN)
Here is the latest stock price and chart of GLAND PHARMA. For more details, see the GLAND PHARMA company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
Announcement: Discover Richa's Top 3 Stock Picks for 2022...
| Live BSE Quotes | May 19, 2022 (Close) | ||
|---|---|---|---|
| Price (Rs)3,095.75 | Open (Rs) 2,920.00 | High (Rs) 3,146.35 | Low (Rs) 2,920.00 |
| % Change-0.30 | Volume 3,793 | Value (Rs) 11,725,755 | 52-Week H/L 4,350.00 / 2,801.00 |
| Live NSE Quotes | May 19, 2022 (Close) | ||
|---|---|---|---|
| Price (Rs)3,099.50 | Open (Rs) 3,050.25 | High (Rs) 3,150.00 | Low (Rs) 3,010.00 |
| % Change-0.30 | Volume 79,539 | Value (Rs) 246,903,906 | 52-Week H/L 4,350.00 / 2,801.00 |
| Change | |||||
|---|---|---|---|---|---|
| 1 Day -0.30% | 1 Month -3.19% | 3 Months -4.69% | 1 Year -7.08% | ||
| Valuation | ||||
|---|---|---|---|---|
| EPS (Rs)* 72.07 | P/E Ratio (x) 42.95 | Market Cap (Rs m) 509,487.70 | P/BV (x) 8.67 | Dividend Yield (%) 0.00 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX 
PERIOD - Advanced Charts new
- Charts by TradingView
GLAND PHARMA Share Price Today:
GLAND PHARMA last traded price was down 0.3% to Rs 3,095.8 on the BSE. On the NSE, GLAND PHARMA last traded price was down 0.3% to Rs 3,099.5. The total volume of shares traded was 0.1 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 2.2%. And the benchmark S&P BSE SENSEX was at 52,792.2 (down 2.6%).
Over the last 30 days, the GLAND PHARMA share price is down 3.4%. And over the last one year, GLAND PHARMA share price is up 1.0%.
The current market capitalisation of GLAND PHARMA stands at Rs 509,487.70 m. For more information, check out the list of top 100 companies in India in terms of market cap.
As of March 2022, company promoters held 58.00% stake in GLAND PHARMA, with no shares having been pledged. To know more, check out the latest shareholding pattern of GLAND PHARMA.
What else is happening in the markets today? Dig in...
- TRACK NOW:
- Most Active Stocks Rs 0 to 10
- Most Active Stocks Rs 10 to 20
- Top Gainers Today BSE A Group
- Top Gainers Today NSE Above Rs 20
- Top Gainers Today BSE Above Rs 20
- Top Gainers Today BSE Sensex
- Top Gainers Today BSE Small Cap
- Top Gainers Today BSE 500
- Top Losers Today BSE A Group
- Most Active Stocks Rs 1 to 2
- Top Losers Today NSE Above Rs 20
- Buzzing Stocks Today
- Most Popular Stocks BSE 30
- TRENDING ON EQUITYMASTER:
- Warren Buffett - The Value Investor
- Your Ultimate Guide to Penny Stock Investing
- How to Invest in Gold
- Basics of Value Investing
- Benjamin Graham
- The Best Bluechip Stocks to Buy
- How to Invest in Silver
- The Best Small-cap Stocks to Buy
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Best Stocks to Buy Today
- How to Use P/E for Successful Investing
- How to Find Undervalued Stocks
- Differences Between Trading and Investing
- SWOT Analysis for Stocks
- The Best Dividend Stocks to Buy
Today's Market
5 Reasons Why Sensex Tumbled 1,416 Points Today(Closing)
Indian share markets remained in the bear grip throughout the trading session today tracking extremely weak global cues.
Related Views On News
Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)
May 19, 2022During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.
Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)
Apr 13, 2022The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?
Nifty Pharma Index - Bulls are Losing the Ground (Views On News)
Mar 16, 2022For the Nifty pharma index, it seems as if bulls are losing ground as they witness multiple bearish candlestick patterns.
IPO Alert! 3 Companies Including PharmEasy Get the Green Light (Views On News)
Feb 22, 2022The strong momentum in India's IPO market is poised to continue with the market regulator approving the IPOs of three firms including PharmEasy.
Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)
Dec 16, 2021In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.
More Views on NewsMost Popular
2022's Best Performing Penny Stocks So Far... (Views On News)
Mar 2, 2022We are just two months into 2022 and several penny stocks that we track have already surged 5x.
5 Debt Free Penny Stocks with Good Profitability to Watch Out for in 2022 (Views On News)
Mar 16, 2022Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.
Penny Stocks to Buy and Hold Beyond 2022 (Views On News)
Apr 6, 2022A step-by-step method to pick the best penny stocks for the long term.
6 Penny Stocks that Could Be Hidden Bluechips. Take a Look... (Views On News)
Apr 13, 2022These penny stocks can become future multibaggers. Watch out for them.
Adani Power vs Tata Power: Which Power Stock is Better? (Views On News)
Feb 28, 2022Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2022
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: How to Profit from Sensex 100,000
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
TRACK GLAND PHARMA
- Track your investment in GLAND PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON GLAND PHARMA
GLAND PHARMA 8-QTR ANALYSIS
COMPARE GLAND PHARMA WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Multibagger Penny Stocks
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Best Small-cap Stocks to Buy
- Best Bluechip Stocks to Buy
- Guide to Penny Stocks
- How to Invest in the Share Market
- Warren Buffett - The Value Investor
- Pick the Best Multibagger Stocks in 2022
FOLLOW
APP
EQUITYMASTER SUPPORTS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.